Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.42 |
| ▸ | TYK2 | P29597 | 3/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL794012 | 0.87 | TYK2 (0.45) | ALDH1A1GPR35TYK2TAS1R3TAS1R1 | |
| SCHEMBL1706740 | 0.83 | GPR35 (0.46) | GPR35TYK2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL7016991 | 0.81 | GPR35 (0.41) | GPR35TYK2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL14059713 | 0.77 | JAK2 (0.38) | ALDH1A1GPR35TYK2VCAM1JAK2 | |
| SCHEMBL1707633 | 0.76 | MRGPRX4 (0.45) | ALDH1A1GPR35TYK2TAS1R3TAS1R1 | |
| SCHEMBL792494 | 0.75 | TYK2 (0.42) | GPR35TYK2JAK2PDK1PDK2 | |
| SCHEMBL21826384 | 0.75 | ALDH1A1 (0.44) | ALDH1A1GPR35TYK2FLT1FLT4 | |
| SCHEMBL333570 | 0.74 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ALMNAMAPT | |
| SCHEMBL6628485 | 0.74 | FLT1 (0.52) | ALDH1A1TAS1R3TAS1R1TAS1R2VCAM1 | |
| SCHEMBL793644 | 0.74 | TYK2 (0.41) | GPR35TYK2TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9364466-B2 | Heterocyclic compounds as protein kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| EP-2714688-B1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20150157613-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8980911-B2 | Heterocyclic compounds as protein kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140155398-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-06-05 | — | — | US | disclosed |
| US-8697708-B2 | Azabenzothiazole compounds, compositions and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-15 | — | — | US | disclosed |
| EP-2616072-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| WO-2012160464-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-29 | — | — | WO | disclosed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| EP-2440529-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012035039-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2010142752-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | ALDH1A1 1560/4885GPR35 2960/4885TYK2 21/4885 |
| US-20150157613-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAP3K1, JAK2, AKT1 | ALDH1A1 1005/4885GPR35 2834/4885TYK2 666/4885 |
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | ALDH1A1 1372/4885GPR35 305/4885TYK2 229/4885 |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | ALDH1A1 1372/4885GPR35 305/4885TYK2 229/4885 |
| US-20140155398-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAP3K1, JAK2, AKT1 | ALDH1A1 1005/4885GPR35 2834/4885TYK2 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.